皮佩林通过抑制URAT1/GLUT9和AKT-mTOR通路来改善高尿路性脏病
Lu Li1, Kunlu Zhao1, Jian Luo1
1NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou 510515, China.
皮皮林是一种天然化合物,在治疗高尿素性脏病 (HN) 中表现有前途. 它有效降低尿酸水平,并通过抑制关键载体和AKT/mTOR通路来保护功能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 自然产品 化学 化学
背景情况:
- 失控的高尿路血症可能导致高尿路血症脏病 (HN),这是一个由炎症和氧化压力标志着的情况.
- 来自肉酸的皮佩林具有已知的抗氧化和抗炎性质.
研究的目的:
- 在小鼠模型中评估 piperine 对诱导高尿素性脏病 (HN) 的保护作用.
- 调查皮佩林对尿酸水平,功能和管状上皮细胞的影响.
主要方法:
- 在小鼠中使用腺因和氧酸盐诱导的HN;用piperine治疗3周.
- 在小鼠管状上皮细胞 (mRTECs) 中利用尿酸诱导的损伤模型.
- 评估了血清尿酸,功能标志物,输送体表达 (URAT1/GLUT9) 和AKT/mTOR通路活性.
主要成果:
- 在HN小鼠中,piperine治疗显著降低了血清尿酸,并改善了功能.
- 皮佩林缓解了尿酸诱导的mRTECs损伤,并抑制了URAT1/GLUT9转运体的活性.
- 皮皮林在体内和体外都调节了AKT/mTOR信号通路.
结论:
- 皮佩林显示出对高尿素性脏病的保护作用.
- 皮皮林通过抑制URAT1/GLUT9载体和AKT/mTOR通路来改善HN.
- 皮佩林是管理高尿素性脏病的潜在治疗候选者.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
15:43Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
相关概念视频
Drug Elimination by Renal Route: Tubular Secretion
Phase II Reactions: Glucuronidation
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
PI3K/mTOR/AKT Signaling Pathway
Renal Drug Excretion: Tubular Secretion
GPCRs Regulate Adenylyl Cylase Activity
